QNZ (EVP4593) is primarily used in research settings as a potent and selective inhibitor of nuclear factor kappa B (NF-κB) activation. It is widely applied in studies focusing on inflammation, immune response, and cancer, where NF-κB signaling plays a critical role. By inhibiting this pathway, it helps researchers understand the molecular mechanisms underlying these processes and evaluate potential therapeutic targets. Additionally, QNZ is utilized in experimental models to investigate its effects on cytokine production, cell survival, and apoptosis, providing insights into diseases characterized by dysregulated NF-κB activity. Its application extends to drug discovery and development, particularly in identifying compounds that can modulate inflammatory and oncogenic pathways.